NCT05704881Recruiting
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
Monitoring of the End-tidal Carbon Dioxide (EtCO2 ) as a Severity Criterion in COPD Exacerbations: a Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 19 Dec 2022
- Start date
- 3 Mar 2023
- Primary completion date
- 3 Sept 2026
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- COPD
- NCT number
- NCT05704881
What you commit to
- Study type: Observational
- Planned participants: 240
- From 3 Mar 2023 to the primary completion date, 3 Sept 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient already included in the study during a previous visit to the emergency department
Other
- Hypotension (SBP \< 90 mmHg or MBP \< 65 mmHg)
- Patient already ventilated with invasive or NIV during admission to the emergency department
- COPD exacerbation rejected after medical and additional examinations
- Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness
- Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
Who the study is looking for
- All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family
- Male or female≥18 years old who did not oppose to participating in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
| Hospices Civils de Lyon Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.